Research
-
October 1, 2021
VUMC research contributed to first COVID-19 pill now under review
Vanderbilt research helped allow pharmaceutical giant Merck & Co. to authorization for the first oral antiviral pill to treat COVID-19. -
September 30, 2021
Molecular imaging of C. diff infection
C. difficile — the leading cause of hospital-associated intestinal infections — induces a rapid influx of bile acids into the gut, which could provide a novel target for blocking infection. -
September 30, 2021
Fibroids and preterm birth
In a large, prospective study, Vanderbilt researchers found no association between fibroids and any clinical subtype of preterm birth, supporting a reconsideration of the impression that fibroids increase preterm birth risk. -
September 30, 2021
Study shows how a protein coding gene confers breast cancer susceptibility during DNA transcription
Vanderbilt-Ingram Cancer Center research is providing new insights into how genetic variants convey breast cancer susceptibility by altering the transcription factor proteins that convert DNA strands into RNA. -
September 29, 2021
Neurotransmitter transporters expert Amara set for Oct. 7 Discovery Lecture
Susan Amara, PhD, scientific director of the Intramural Research Program at the NIMH and an expert on the biology of neurotransmitter transporters, will deliver Vanderbilt's next Discovery Lecture via Zoom at 4 p.m., Thursday, Oct. 7. -
September 21, 2021
The role of polarity in early cancer
Mutations in the protein epiregulin, an EGF receptor ligand, affect larger epithelial cell reorganization and may contribute to early cancer development, Vanderbilt researchers discovered. -
September 20, 2021
Brain circuits in schizophrenia
Vanderbilt psychiatrists are probing brain circuit hyperactivity implicated in schizophrenia, with the idea that normalizing the hyperactivity may improve cognitive processes.